Now the dust has settled over immune checkpoint blockade in metastatic prostate cancer

Ann Oncol. 2018 Aug 1;29(8):1620-1622. doi: 10.1093/annonc/mdy239.

Authors

N Mehra¹, W Gerritsen²

Affiliations

¹ Department of Medical Oncology, Radboud University Medical Center and the Tumour Immunology Laboratory, Radboud Institute of Molecular Life Sciences, Nijmegen, The Netherlands. Electronic address: niven.mehra@radboudumc.nl.
² Department of Medical Oncology, Radboud University Medical Center and the Tumour Immunology Laboratory, Radboud Institute of Molecular Life Sciences, Nijmegen, The Netherlands.

PMID: 29992258
DOI: 10.1093/annonc/mdy239

No abstract available

Publication types

Editorial
Comment

MeSH terms

Adenocarcinoma*
Antibodies, Monoclonal, Humanized
Dust
Humans
Male
Prostatic Neoplasms*

Substances

Antibodies, Monoclonal, Humanized
Dust
pembrolizumab